AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein-glucosylgalactosylhydroxylysine glucosidase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q32M88

UPID:

PGGHG_HUMAN

Alternative names:

Acid trehalase-like protein 1

Alternative UPACC:

Q32M88; Q658X8; Q8TEG9; Q9H635

Background:

Protein-glucosylgalactosylhydroxylysine glucosidase, also known as Acid trehalase-like protein 1, plays a crucial role in the metabolism of collagen and collagen-like proteins by catalyzing the hydrolysis of glucose from disaccharide units linked to hydroxylysine residues. This enzymatic activity is essential for the proper processing and turnover of collagen, a key structural component of the extracellular matrix in various tissues.

Therapeutic significance:

Understanding the role of Protein-glucosylgalactosylhydroxylysine glucosidase could open doors to potential therapeutic strategies. Its involvement in collagen metabolism suggests its potential impact on diseases related to extracellular matrix disorders, offering a promising avenue for research into novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.